Metabotropic glutamate receptor 5: a target for migraine therapy.

ABSTRACT:

Introduction

Many patients suffering from migraine gain little relief from existing treatments partly because many existing acute and preventive therapies used in migraine have been adopted from other neurologic conditions such as depression or epilepsy. Here, we present data supporting a new migraine-specific target, the mGlu5 receptor.

Methods

We studied the effect of mGlu5 blockade using ADX10059, on neuronal firing in the trigeminocervical complex (TCC) and durovascular effects of nociceptive trigeminovascular activation in the anesthetized rat. The clinical potential of the mGlu5 mechanism was tested with ADX10059 orally in a double-blind placebo-controlled, parallel group, clinical trial.

Results

The negative allosteric mGlu5 modulator ADX10059 attenuated dural

SUBMITTER: Waung MW 

PROVIDER: S-EPMC4999590 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature